Results 171 to 180 of about 1,720,825 (280)

Chimeric antigen receptor technology: an emerging translational immunotherapy in nonneoplastic diseases. [PDF]

Front Immunol
Zhou S, Li Y, Zhao J, Zhan W, Zhou C, Zou Y, Li X, Cui J, Wu J, Xia J.   +9 more
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Real-world prevalence and prognostic significance of hepatotoxicity after chimeric antigen receptor T-cell therapy. [PDF]

Br J Haematol
Hollnberger J, Richardson T, Gödel P, Leutiger J, Schumacher JC, Schiestel S, Allhoff B, Scheid C, Holtick U, Neumann-Haefelin C, Allo G, Kasper P.   +11 more
europepmc   +1 more source

Precision medicine in paediatrics: Progress and priorities

British Journal of Clinical Pharmacology, EarlyView.
Precision medicine is revolutionizing personalized healthcare, advancing both diagnostics and therapeutics at an unprecedented pace. Reviewing the paediatric applications of pharmacometrics, pharmacogenomics and advanced therapy medicinal products highlights not only the relevance of these exciting innovations to frontline care but also the significant
Nicola Husain, Claire Booth, Joseph F. Standing, Charlotte I. S. Barker   +3 more
wiley   +1 more source

Real-world outcomes for multiple myeloma patients after apheresis for planned chimeric antigen receptor T-cell therapy. [PDF]

World J Exp Med
Bangolo A, Gill S, Zhang L, Zhao J, Amoozgar B, Reich-Slotky R, Tran J, Vo T, Mariblanca G, Balulescu X, Mcknight S, Patel N, Reed A, Kaur S, Subramanian S, Katyal J, Manikkuttiyil C, Chakov M, Nguyen A, Pashine S, Khalil A, Mathew S, Gill R, Andrews V, Ordonez P, Olson B, Koleng M, Persaud R, Saride HS, Dharsi M, Thach R, Chen W, Shahid M, Weissman S, Siegel D, Parmar H, Biran N, Vesole DH, Phull P.   +38 more
europepmc   +1 more source

Ferritin as a Nanoparticle Scaffold for Plant‐Produced Next‐Generation Subunit Vaccines

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Protein nanoparticles offer an innovative approach to next‐generation subunit vaccine development by displaying antigenic sequences on the nanoparticle surface. Compared to traditional subunit vaccines, protein nanoparticle vaccines often show improved interaction with the immune system due to their particulate size and repetitive epitope ...
Jordan T. VanderBurgt, Richard Strasser, Christopher P. Garnham, Rima Menassa   +3 more
wiley   +1 more source

Chimeric antigen receptor T-cell therapy in neuroimmune diseases: mechanistic rationale, clinical experience, and translational challenges. [PDF]

Front Immunol
Yi Y, Xiao H, Yin Y, Zeng R, Yan Q, Wu Y, Yang K, Fu G, Xu H, Zhang X.   +9 more
europepmc   +1 more source

Isolating T‐Cell Potent Lentiviral Vector Subpopulations through Rational Design of Nanofiber Anion‐Exchange Adsorbents

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Generation of CAR‐T cell therapies relies predominantly on lentiviral vectors (LVs). As in vivo CAR‐T trials progress, demand for larger quantities of higher‐potency LV is expected. However, primary capture by anion‐exchange chromatography (AIEX) remains a major manufacturing bottleneck from use of adsorbents not tailored to LVs, leading to ...
George Pamenter, Gyorgy Ovari, Anurag Kulkarni, Thomas Williams‐Fegredo, Carol Knevelman, Kyriacos Mitrophanous, Lee Davies, Farzad Foroutan, Matthew Townsend, Stephen Goldrick, Daniel G. Bracewell   +10 more
wiley   +1 more source

The role and potential of CD19-targeted chimeric antigen receptor T-cell therapy in systemic sclerosis. [PDF]

Reumatologia
Michalak K, Chlebowska G, Sędziak O, Woszczyk D.   +3 more
europepmc   +1 more source

Cell and Gene Therapies Manufacturing Challenges and Integrated Good Manufacturing Practices Solutions: A Lifecycle Perspective

Biotechnology and Bioengineering, EarlyView.
Lifecycle perspective on cell and gene therapy manufacturing challenges and enabling GMP solutions. ABSTRACT Cell and gene therapies (CGTs) are revolutionizing modern medicine; however, making these advanced medicines scalable and readily available to commercial manufacturers worldwide is a major challenge. The number of approved CGT products continues
Rajath Samaga, Udisha Singh, Sachin Dattram Pawar   +2 more
wiley   +1 more source